Tag Directory / PHARMACEUTICALS     showing 1–8 of 8

for: Saturday, March 14, 2026



A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices / Medical Express

medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch

Dark sweet cherries may help slow aggressive breast cancer, mouse study suggests

36 hrs / medicalxpress

Oluwasanmi Ajagbe: Lay Notes About Triple Negative Breast Cancer

37 hrs / oncodaily

A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices

3 days / medicalxpress

How a Reproductive Gene Could Hold the Key to Treating Triple Negative Breast Cancer – ICR

4 days / oncodaily

Saturday, March 14, 2026, 11:21 pm / permalink 20776 / 4 stories in 45 hrs


Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision / MedCity

Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #healthcarefinance

Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision

7 days / medcitynews / Frank Vinluan

GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront

7 days / endpoints / Reynald Castaneda

Saturday, March 14, 2026, 8:21 pm / permalink 20771 / 2 stories in 2 days


Roche’s big hope breast cancer drug fails in crucial first-line trial / Endpoints

Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch

DARE Trial: Phase II Study of ctDNA-Guided Intervention in ER+/HER2− Early Breast Cancer — Investigator Perspective

7 hrs / oncodaily

BRCA2-Driven Breast Cancer May Follow A Different Resistance Path On CDK4/6 Inhibitors

17 hrs / oncodaily

Natera Announces Webinar on PALLAS and LEADER Studies in Early Breast Cancer

2 days / oncodaily

1 in 3 Americans make financial trade-offs to afford healthcare: Gallup

4 days / beckershospitalreview / Kristin Kuchno

Roche’s big hope breast cancer drug fails in crucial first-line trial

7 days / endpoints / Elizabeth Cairns

Saturday, March 14, 2026, 7:21 pm / permalink 20770 / 5 stories in 2 days


‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up / MedCity

Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #digitalhealth #healthcarefinance #supplychain

FDA warns Novo Nordisk broke safety reporting rules

2 days / medicalxpress

‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up

4 days / medcitynews / Marissa Plescia

Watch: Who won the Hims vs. Novo feud?

6 days / endpoints / Lydia Ramsey Pflanzer

Saturday, March 14, 2026, 2:22 pm / permalink 20763 / 3 stories in 2 days


Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia / OncoDaily

oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch

Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia

2 days / oncodaily

Romiplostim prevents serious side effect of chemotherapy in phase 3 trial

4 days / medicalxpress

Saturday, March 14, 2026, 12:23 pm / permalink 20760 / 2 stories in 2 days


Ipsen pulls cancer drug Tazverik from market over safety risks / Endpoints

Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #productrecall #oncology #cancerresearch

BioMarin halts Phase 2 Voxzogo dosing in certain patients over safety concern

6 hrs / endpoints / Nicole DeFeudis

Cancer drug pulled from US market

6 days / beckershospitalreview / Paige Twenter

Ipsen pulls cancer drug Tazverik from market over safety risks

7 days / endpoints / Nicole DeFeudis

Saturday, March 14, 2026, 12:23 am / permalink 20738 / 3 stories in 2 days


Eliquis may be safer than Xarelto for patients with deep blood clots: Study / Beckers

Ella Jeffries / beckershospitalreview - Patients taking blood thinner Eliquis had a lower risk of clinically relevant bleeding than those taking Xarelto, a recent study found. Researchers enrolled 2,760 patients with venous thrombosis — blood clots in the veins of the legs or lungs — and random…

#healthcare #pharmaceuticals #publichealth #drugdevelopment

Eliquis may be safer than Xarelto for patients with deep blood clots: Study

3 days / beckershospitalreview / Ella Jeffries

Safer blood clot treatment: Apixaban beats rivaroxaban in head-to-head comparison

5 days / medicalxpress

Saturday, March 14, 2026, 12:23 am / permalink 20737 / 2 stories in 2 days


Flu vaccines didn't work that well in the US, officials find / Medical Express

medicalxpress - As the U.S. flu season winds down, health officials say the flu vaccine didn't work very well, with one of its worst effectiveness rates in more than a decade.

#healthcare #pharmaceuticals #publichealth #drugdevelopment #cdc #vaccinesafety #infectiousdisease

CDC: Influenza vaccine during 2025 to 2026 season less effective than previous seasons

4 hrs / medicalxpress

Flu vaccines didn't work that well in the US, officials find

3 days / medicalxpress

Flu vaccines didn't work that well in the US, officials find

3 days / abcnews

Saturday, March 14, 2026, 12:23 am / permalink 20736 / 3 stories in 2 days


Back to Top


PHARMACEUTICALS Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.